Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.63 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | PPARA | Q07869 | 4/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6104143 | 0.88 | LTB4R (0.57) | FFAR1S1PR1S1PR3S1PR5LTA4H | |
| SCHEMBL3837954 | 0.85 | FFAR1 (0.51) | FFAR1S1PR1S1PR3S1PR5LTA4H | |
| SCHEMBL3838043 | 0.85 | LTB4R (0.54) | FFAR1S1PR1S1PR3S1PR5LTA4H | |
| SCHEMBL27541878 | 0.83 | OPRK1 (0.56) | FFAR1PPARGPPARAMEN1KMT2A | |
| SCHEMBL949517 | 0.80 | LTA4H (0.77) | FFAR1S1PR1S1PR3S1PR5LTA4H | |
| SCHEMBL12156601 | 0.79 | RAB9A (0.51) | KCNH2LTA4HPPARGPPARAMEN1 | |
| Hydrochloric Acid SCHEMBL4658264 | 0.79 | LTA4H (0.75) | FFAR1S1PR1S1PR3S1PR5LTA4H | |
| SCHEMBL1746597 | 0.78 | FFAR1 (1.00) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL4656572 | 0.76 | FFAR1 (0.97) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL910747 | 0.76 | KCNH2 (0.58) | FFAR1S1PR1S1PR3S1PR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| CN-1301980-C | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2007-02-28 | — | — | CN | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| CN-1701064-A | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2005-11-23 | — | — | CN | disclosed |
| EP-1529038-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016601-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | FFAR1 183/4885S1PR1 1324/4885S1PR3 1432/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | FFAR1 183/4885S1PR1 1324/4885S1PR3 1432/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | FFAR1 363/4885S1PR1 1668/4885S1PR3 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.